Compare MMLP & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MMLP | TNXP |
|---|---|---|
| Founded | 2002 | 2007 |
| Country | United States | United States |
| Employees | N/A | 142 |
| Industry | Oil Refining/Marketing | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.0M | 88.0M |
| IPO Year | 2002 | 2008 |
| Metric | MMLP | TNXP |
|---|---|---|
| Price | $2.07 | $5.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $44.50 |
| AVG Volume (30 Days) | 25.6K | ★ 929.5K |
| Earning Date | 10-21-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | ★ 91.75 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,653,009,000.00 | $13,107,000.00 |
| Revenue This Year | N/A | $319.65 |
| Revenue Next Year | N/A | $101.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.65 | ★ 29.85 |
| 52 Week Low | $1.76 | $5.05 |
| 52 Week High | $3.24 | $20.58 |
| Indicator | MMLP | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 49.78 | 13.33 |
| Support Level | $1.83 | N/A |
| Resistance Level | $2.42 | $12.99 |
| Average True Range (ATR) | 0.16 | 0.51 |
| MACD | 0.02 | -0.07 |
| Stochastic Oscillator | 69.39 | 3.92 |
Martin Midstream Partners LP has a diverse set of operations focused on the United States Gulf Coast region. The company's business lines include terminalling, processing, storage, and packaging services for petroleum products and by-products, including the refining of naphthenic crude oil; land and marine transportation services for petroleum products and by-products, chemicals, and specialty products; sulfur and sulfur-based products processing, manufacturing, marketing, and distribution; and natural gas liquids marketing, distribution and transportation services. The company operates in four segment Terminalling and storage, Transportation, Sulfur service, and Specialty products segment. The majority of the revenue is derived from the Specialty products segment.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.